Exactmer Partners with Asahi Kasei Bioprocess to Accelerate Growth of Nanostar Sieving Technology for Large-scale Oligo Manufacturing
LONDON — August 8th, 2024 — Oligonucleotide-based therapies have emerged as powerful tools in modern medicine, with several FDA-approved treatments already on the market. The global multibillion-dollar oligonucleotide synthesis market is expected to continue expanding at double-digit growth rates over the coming years as drug manufacturers look for new ways to advance life-saving therapeutics.
Exactmer, a pioneer in polymer synthesis and manufacturing services, has received investment from Asahi Kasei Medical (AKM) to accelerate the growth of its innovative “Nanostar Sieving” technology within the oligonucleotide space. In conjunction with the investment, Exactmer and Asahi Kasei Bioprocess, part of Asahi Kasei Medical, offering technology platforms for oligonucleotide synthesis, have agreed to explore technical collaboration aimed at rapidly scaling Exactmer’s technology to meet emerging customer applications.
Exactmer’s proprietary platform technology, Nanostar Sieving, allows large-scale manufacturing of exact polymers, including oligonucleotides, fully in solution. This innovative approach overcomes current limitations in oligonucleotide production, making advanced therapies more accessible to patients in need.
“Asahi Kasei Bioprocess’ support will be instrumental in scaling our Nanostar Sieving technology and helping us address the growing demand for oligonucleotide-based therapies that contribute to the next wave of breakthrough treatments,” said Andrew Livingston, Chief Executive Officer and Co-Founder of Exactmer.
The investment and technical collaboration will support the commercial development of large-scale synthesis solutions that significantly reduce solvent usage, addressing both economic and environmental concerns in oligonucleotide pharmaceutical manufacturing. Both Exactmer and Asahi Kasei Bioprocess are committed to advancing the field of oligonucleotide therapeutics and look forward to the positive impact this partnership will have on the industry and patient care.
“This groundbreaking technology has the potential to transform how these critical therapeutics are manufactured, offering increased efficiency, reduced costs, and improved environmental sustainability,” said Chris Rombach, Executive Vice President at Asahi Kasei Bioprocess. He added: “With this investment and the planned collaboration – both of which align with Asahi Kasei Bioprocess’ mission to help customers achieve long term productivity gains by pushing the boundary of tomorrow’s technology today – we’re jointly accelerating our growth in the oligonucleotide synthesis market by leveraging Exactmer’s technology to build cutting-edge equipment and provide consultative expertise to customers.”
Learn more about how Nanostar Sieving works.
About Exactmer
Exactmer is a life sciences company with the mission to manufacture exact polymeric pharmaceuticals, enabling advanced therapies to be provided to all patients in need. Exactmer specializes in the synthesis of biopolymers (oligonucleotides, peptides) and synthetic polymers (polyethylene glycols) using its patented Nanostar Sieving Technology, which allows the synthesis of polymers with exactly defined monomer sequences in liquid phase. Exactmer produces polymers of unprecedented precision by using this completely new approach, opening the way to manufacture at scale supremely accurate polymers for use as pharmaceuticals. For more information please visit: https://exactmer.com/.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922, it has consistently grown its business portfolio to meet the evolving needs of every age. Now with more than 49,000 employees worldwide, it aims to provide solutions to the world’s sustainability challenges through its three business sectors of Health Care, Homes, and Material. Asahi Kasei Medical is a core operating company in the group’s Health Care sector. Its bioprocess business arm – Asahi Kasei Bioprocess – is devoted to solving product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. Along with its technology platforms for oligonucleotide synthesis, buffer formulation, chromatography and filtration, its bioprocess systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. For more information, please visit: https://fluidmgmt.ak-bio.com.
Asahi Kasei Bioprocess – Built with pride, built with quality, built to exceed expectations. “Built for You.”
Contact
